Mirum Pharmaceuticals Inc (MIRM) Institutional Investor Snapshot (332 Funds, Q2 2026)

MIRM ranks #1903 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MIRM is a top-conviction position for Frazier Life Sciences Management, L.P. — at 19.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Versant Capital Management, Inc has added to its MIRM position for two straight quarters, increasing it by $7.0K to reach $12.3K today.

Farther Finance Advisors, LLC has trimmed its MIRM position for two straight quarters, cutting it by $6.6K while still holding $3.8K.

MIRM is up 0.9% today, and institutions have been net buyers of $1.3B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MIRM reported a net loss of $860.2M over the trailing twelve months.

• Not yet profitable — net loss of $860.2M over the trailing twelve months
• Revenue grew 44.0% year over year
• Net income declined year over year, from -$58.6M to -$860.2M
• Generated $55.8M in positive operating cash flow
• Current ratio of 2.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.68x equity — within a conventional range